The present invention relates to a formulation providing anti-aging benefits that may include ingredients from various ingredient groups such as amino acids, vitamins or mineral co-factors, antioxidants or carotenoids, an herbal, plant derivative, or phytonutrients, and other nutrients. When combined, these ingredients and, more specifically, the herbal, plant derivative, or phytonutrients blend provide increased and unexpected synergistic effects that inhibit DPP4 activity and provide anti-aging benefits.

The present invention relates to a formulation providing anti-aging benefits that may include ingredients from various ingredient groups such as amino acids, vitamins or mineral co-factors, antioxidants or carotenoids, an herbal, plant derivative, or phytonutrients, and other nutrients. When combined, these ingredients and, more specifically, the herbal, plant derivative, or phytonutrients blend provide increased and unexpected synergistic effects that inhibit DPP4 activity and provide anti-aging benefits.

The present invention relates to a formulation providing anti-aging benefits that may include ingredients from various ingredient groups such as amino acids, vitamins or mineral co-factors, antioxidants or carotenoids, an herbal, plant derivative, or phytonutrients, and other nutrients. When combined, these ingredients and, more specifically, the herbal, plant derivative, or phytonutrients blend provide increased and unexpected synergistic effects that inhibit DPP4 activity and provide anti-aging benefits.

Compositions comprising microbiome regulators are provided, as well as methods of using the same for the modulation of the human microbiota and to treat or prevent related diseases, disorders, or conditions.

Compositions comprising microbiome regulators are provided, as well as methods of using the same for the modulation of the human microbiota and to treat or prevent related diseases, disorders, or conditions.

Injectable baclofen formulations and methods that are bioequivalent in terms of plasma baclofen exposure to oral dosage forms but with reduced exposure ratios of baclofen to the M1 metabolite.

Injectable baclofen formulations and methods that are bioequivalent in terms of plasma baclofen exposure to oral dosage forms but with reduced exposure ratios of baclofen to the M1 metabolite.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

The present invention relates to the field of therapeutics and, more in particular, to pharmaceutical compositions for the prevention and/or treatment of bacterial infections and antibacterial-induced dysfunctions. The invention is based on the identification of compounds that prevent antibacterial effects of antibiotics on microbiome-bacterial species, while retaining antibacterial effects of antibiotics on pathogenic bacteria. The invention also pertains to pharmaceutical compositions comprising antibiotics and antibiotic antidotes for the protection of commensal microbiome-bacteria. Thus, this invention relates to compounds and pharmaceutical combinations useful to prevent antibiotic-induced adverse effects on the gut microbiome. Furthermore provided are methods for preventing an adverse effect on a gut microbiome using the compounds and/or pharmaceutical compositions of this invention.

Aspects of the disclosure relate to compositions and methods for dietary management of certain conditions, such as infectious diseases. The disclosure is based, in part, on methods of identifying one or more single nucleotide polymorphisms (SNPs) in a subject and preparing a personalized report recommending a mixture of nutritional supplements and/or dietary aids based upon the presence of the SNPs. In some embodiments, the disclosure provides personalized compositions comprising nutritional supplements for dietary management of immune health and COVID support.